NovaBay Pharma terminates Alcon licensing deal
Aganocide compounds are indicated for the topical treatment and prevention of antibiotic-resistant infections. As a part of the termination, NovaBay is entitled to receive a sum of $2,972,245
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.